Skip to main content

Table 1 Patient baseline characteristics

From: Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease

  Male
N = 82
Female
N = 54
p value
Age (years) 65.2 (6.8) 63.6 (8.1) 0.24
Race
 White, % 77(94) 50 (93)  
 Black or African American, % 3 (4) 2 (4) 0.84
 Others, % 2 (2) 2 (4)  
 Body mass index 27.2 (4.9) 27.2 (5.5) 0.98
 Former smokers, % 50 (61) 26 (48) 0.16
Post-bronchodilator FEV1
 Absolute (L) 1.4 (0.5) 1.2 (0.4) 0.0036
 % predicted 43.8 (15.5) 51.3 (13.6) 0.0043
 Post-bronchodilator FEV1/FVC ratio 0.45 (0.1) 0.52 (0.1) 0.00024
 SGRQ-C score 57.9 (17.3) 57.1 (18.3) 0.80
GOLD, %
 Stage II 31 (38) 32 (59)  
 Stage III 31 (38) 18 (33) 0.011
 Stage IV 20 (24) 4 (7)  
Patients with bronchodilator reversibility, % 14 (17) 6 (11) 0.46
Patients with chronic bronchitis, % 67 (82) 41 (76) 0.52
Patients with severe exacerbation in previous 12 months, % 26 (32) 11 (20) 0.17
Median blood eosinophil count (cells per μL) 180 (130) 175 (183) 0.89
Median fibrinogen (g/L) 3.8 (1.4) 3.5 (0.9) 0.037
  1. Data are n (%), mean (SD), or median (IQR). FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SGRQ-C, St. George’s Respiratory Questionnaire COPD